BIOA logo

BIOA
BioAge Labs Inc.

515
Mkt Cap
$798.72M
Volume
509,420.00
52W High
$24.00
52W Low
$3.67
PE Ratio
-7.55
BIOA Fundamentals
Price
$18.16
Prev Close
$17.99
Open
$17.99
50D MA
$18.26
Beta
1.35
Avg. Volume
390,866.24
EPS (Annual)
-$2.24
P/B
2.13
Rev/Employee
$145,080.64
$199.85
Loading...
Loading...
News
all
press releases
BioAge Labs (NASDAQ:BIOA) Trading 8.6% Higher - Here's Why
BioAge Labs (NASDAQ:BIOA) Shares Up 8.6% - What's Next...
MarketBeat·14d ago
News Placeholder
More News
News Placeholder
Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell
Wall Street Zen downgraded BioAge Labs from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·17d ago
News Placeholder
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile
BioAge Labs (NASDAQ:BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 inhibitor BGE-102, highlighting what the company characterized as deep reductions in inflammatory...
MarketBeat·17d ago
News Placeholder
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.
Zacks·19d ago
News Placeholder
BioAge Labs (NASDAQ:BIOA) Stock Price Down 6.1% - Time to Sell?
BioAge Labs (NASDAQ:BIOA) Trading Down 6.1% - What's Next...
MarketBeat·19d ago
News Placeholder
BioArctic publishes the Annual Report and Sustainability Report for 2025
BioArctic publishes the Annual Report and Sustainability Report for 2025 BioArctic publishes the Annual Report and Sustainability Report for 2025 PR Newswire STOCKHOLM, April 21, 2026 STOCKHOLM...
PR Newswire·20d ago
News Placeholder
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
The mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·21d ago
News Placeholder
BioAge Labs (NASDAQ:BIOA) Shares Up 10.3% - Still a Buy?
BioAge Labs (NASDAQ:BIOA) Trading Up 10.3% - Here's What Happened...
MarketBeat·24d ago
News Placeholder
BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham Conference
BioAge Labs (NASDAQ:BIOA) used a presentation at the 25th Annual Needham Virtual Healthcare Conference to outline near-term clinical catalysts for its lead NLRP3 inflammasome inhibitor and provide updates on additional pipeline programs and its cash position. Chief Financial Officer Dov Goldstein a...
MarketBeat·25d ago
News Placeholder
BioAge Labs (NASDAQ:BIOA) Shares Down 6% - Here's What Happened
BioAge Labs (NASDAQ:BIOA) Shares Down 6% - Here's What Happened...
MarketBeat·1mo ago
<
1
2
...
>

Latest BIOA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.